HUTCHMED (NASDAQ:HCM) Upgraded to “Hold” at Zacks Investment Research

HUTCHMED (NASDAQ:HCM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong. “

Several other analysts have also recently commented on the company. Jefferies Financial Group started coverage on HUTCHMED in a report on Tuesday, August 3rd. They set a “buy” rating and a $52.00 target price on the stock. Cantor Fitzgerald increased their target price on HUTCHMED from $40.00 to $45.00 and gave the stock an “overweight” rating in a report on Tuesday, July 13th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, HUTCHMED currently has an average rating of “Buy” and a consensus target price of $44.25.

NASDAQ:HCM traded down $0.90 during trading hours on Tuesday, reaching $39.14. The company had a trading volume of 120,445 shares, compared to its average volume of 306,043. The stock has a 50-day moving average of $39.88 and a two-hundred day moving average of $32.91. HUTCHMED has a one year low of $23.67 and a one year high of $43.94. The firm has a market capitalization of $6.76 billion, a PE ratio of -43.49 and a beta of 1.08. The company has a quick ratio of 4.30, a current ratio of 4.41 and a debt-to-equity ratio of 0.05.

Institutional investors have recently made changes to their positions in the business. Quadrant Capital Group LLC increased its holdings in shares of HUTCHMED by 227.3% in the second quarter. Quadrant Capital Group LLC now owns 635 shares of the company’s stock worth $25,000 after acquiring an additional 441 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in HUTCHMED by 36.0% in the second quarter. PNC Financial Services Group Inc. now owns 2,622 shares of the company’s stock valued at $104,000 after purchasing an additional 694 shares in the last quarter. Ensign Peak Advisors Inc grew its stake in HUTCHMED by 300.0% in the first quarter. Ensign Peak Advisors Inc now owns 5,200 shares of the company’s stock valued at $147,000 after purchasing an additional 3,900 shares in the last quarter. Lazard Asset Management LLC bought a new position in HUTCHMED in the second quarter valued at approximately $199,000. Finally, Nomura Asset Management Co. Ltd. bought a new position in HUTCHMED in the second quarter valued at approximately $204,000. Institutional investors own 26.60% of the company’s stock.

About HUTCHMED

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products.

Recommended Story: Federal Reserve

Get a free copy of the Zacks research report on HUTCHMED (HCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.